NFO Alert: Invesco Mutual Fund Launches Invesco India Pharma and Healthcare Fund

Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme in the Equity – Sectoral/Thematic category. 

The New Fund Offer (NFO) opened on August 18, 2026, and will close on September 1, 2026. The offer price is ₹10 per unit. 

The minimum lump-sum investment is ₹1,000. Investors can also start a SIP with ₹100. Further investments can be made in multiples of ₹1. 

Fund Manager and Benchmark 

Aditya Khemani, Head of Equity and Fund Manager at Invesco Mutual Fund, will manage the scheme. 

The fund will use the BSE Healthcare Total Return Index as its benchmark. It has been assigned a ‘Very High’ risk level. The scheme has Growth, IDCW and IDCW-Reinvestment options. 

Investment Portfolio 

The fund will invest mainly in shares and equity-related securities of companies in the pharmaceutical, healthcare, and allied sectors. 

The portfolio could include pharmaceutical companies, hospitals, diagnostic businesses, CDMOs, CROs, medical device companies, and healthcare service providers. 

Investments may also be made in insurance companies and other businesses connected with healthcare. The scheme is therefore not restricted to pharmaceutical stocks. 

Stated Fund Objective 

As per the stated objective, the fund is to generate long-term capital appreciation by investing predominantly in companies operating across pharmaceuticals, healthcare, and allied sectors. 

The fund house has referred to higher healthcare spending, insurance coverage, an ageing population, lifestyle-related diseases, and healthcare infrastructure. 

It has also pointed to India's role in pharmaceutical manufacturing and outsourcing, along with developments in healthcare and life sciences. 

Exit Load 

An exit load of 0.5% will apply when units are redeemed or switched out within three months from the date of allotment. 

No exit load will be charged after the three-month period. The scheme does not provide any assurance that its investment objective will be achieved. 

Read More: Abakkus Mutual Fund AUM Surpasses ₹10,000 Crore Within 8 Months of Launch! 

Conclusion 

The NFO of Invesco India Pharma and Healthcare Fund will remain open until September 1, 2026. The scheme has a ₹10 offer price, ₹1,000 minimum lump-sum investment and ₹100 minimum SIP.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Mutual Fund Investments are subject to market risks, read all the related documents carefully before investing.